Search Within

John Frank Gerecitano

Formats
  1. Meeting Abstract (100)
  2. Journal Article (51)
  3. Book Section (1)
  4. Book Whole (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Center for Hematologic Malignancies (82)
  4. Lymphoma (75)
  5. Survivorship Research (56)
  6. Executive Committee, Center for Hematologic Malignancies (45)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Paul Hamlin (60)
  3. Craig Moskowitz (57)
  4. David Straus (56)
  5. Ariela Noy (50)
  6. Matthew Matasar (48)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (8)

More Years

Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (34)
  3. Haematologica (11)
  4. Clinical Cancer Research (9)
  5. Hematological Oncology (8)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. American Society of Clinical Oncology (34)
  3. American Association for Cancer Research (11)
  4. Ferrata Storti Foundation (11)
  5. Wiley Blackwell (10)
  6. Oxford University Press (7)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia - Results from pre-planned interim analysis of the randomized phase 3 Murano study
    Meeting Abstract

    Seymour, J. F.; Kipps, T. J.; Eichhorst, B. F.; Hillmen, P.; D'Rozario, J. M.; Assouline, S.; Owen, C. J.; Gerecitano, J.; Robak, T.; De la Serna, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Response to the EZH2 inhibitor tazemetostat is independent of cell of origin determined via Hans imunohistochemistry or nanostring lymphoma subtyping test in EZH2 wild-type DLBCL patients
    Meeting Abstract

    McDonald, A. A.; Morschhauser, F.; Ribrag, V.; McKay, P.; Salles, G.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Dickinson, M. J.; Assouline, S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse
    Meeting Abstract

    Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Discovery of candidate predictors of response to tazemetostat in diffuse large B-cell lymphoma and follicular lymphoma using NGS technology on ctDNA samples collected pre-treatment
    Meeting Abstract

    Daigle, S.; McDonald, A. A.; Morschhauser, F.; Salles, G.; Ribrag, V.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Fruchart, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Active surveillance for newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
    Meeting Abstract

    Borchmann, S.; Joffe, E.; Moskowitz, C. H.; Zelenetz, A. D.; Noy, A.; Portlock, C. S.; Gerecitano, J. F.; Batlevi, C.; Caron, P.; Drullinsky, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
    Journal Article

    Younes, A.; Salles, G.; Martinelli, G.; Bociek, R. G.; Barrigon, D. C.; González Barca, E.; Turgut, M.; Gerecitano, J.; Kong, O.; Pisal, C. B.; more...
    Haematologica (2017)

    Fulltext@MSK | Save